A2 Milk (ASX:A2M) share price in focus on China approval

The A2 Milk Company Ltd (ASX:A2M) share price is under the spotlight after the company's positive China news.

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

The A2 Milk Company Ltd (ASX: A2M) share price is under the spotlight after the company’s positive China news.

A2 Milk is one of the largest infant formula makers in Australia and New Zealand.

SAMR approval

A2 Milk and Synlait Milk Ltd (ASX: SM1) announced that Synlait has received approval from China’s State Administration for Market Regulation (SAMR) for the re-registration of A2 Milk’s China label infant milk formula product, stages one, two and three, formulated in line with China’s new GB standards.

This approval will allow Synlait, which manufactures infant formula for A2 Milk, to manufacture for A2 Milk until September 2027, being five years after the expiry of the first registration.

Synlait noted that this SAMR registration is for its Dunsandel facility.

The CEO of Synlait, Grant Watson, said:

Our shareholders, staff, customers, and farmer suppliers all benefit from the certainty of today’s re-registration and continued China market access.

Synlait and The a2 Milk Company have a long-standing and complementary partnership, and we look forward to continuing to support their China growth ambitions. The re-registration is a very important milestone and we have worked hard together to ensure its success. We thank SAMR and the Ministry for Primary Industries, for their support during this process.

A2 Milk response

The A2 Milk Managing Director and CEO David Bortolussi said:

We look forward to making our upgraded new China label IMF product available to parents and their infants and young children in China, building on the strong brand loyalty we have developed with Chinese families over the past decade as the pioneer and leader of the A2 protein category.

The approval provides a2MC with continued access to China’s substantial registered domestic infant milk formula market which remains the key focus of our refreshed growth strategy.

Final thoughts on the A2 Milk share price

The infant formula business needs to be able to keep accessing the key Chinese market – that’s a huge market, and the end customers make up a lot of A2 Milk’s earnings base.

A2 Milk could have had a bad reaction if it wasn’t approved, but I think this enable the ASX share to continue its business as usual.

If it can keep growing earnings

online pharmacy imodium no prescription with best prices today in the USA

over time, the A2 Milk share price could keep rising, but it has a lot of reliance on the China market, which has proven to be a risk, why is why it’s not one of the ASX growth shares on my own watchlist.

Live webinar (with Q&A)

Earnings Season Whiplash
Why prices jump and crash, and how to think clearly when results hit

  • Presented by Owen Rask & Leigh Gant
  • Monday, 16 February   | 7pm AEDT 
At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Build a better financial future, one Sunday at a time

Join over 50,000 savvy Australians receiving Rask’s free weekly email packed with investing insights, personal finance education, and the global stories that can shape your money decisions.


Because breaking down the barriers to finance is how more people learn to invest, build wealth and live life on their terms.

Download the ETF investing mini-series
checklist to follow along

We've created a free resource just for you: a simple editable checklist designed to accompany the podcast series that helps you apply what you learn as you go.

By downloading, you agree to receive emails from us. You can unsubscribe anytime.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.